📊 SYK Key Takeaways
Is Stryker Corp. (SYK) a Good Investment?
Stryker demonstrates exceptional financial health with robust revenue growth of 11.2% YoY, strong profitability (12.9% net margin), and excellent cash generation (4.3B FCF). The company maintains a healthy balance sheet with conservative leverage (0.66x debt/equity), solid liquidity (1.89x current ratio), and strong interest coverage (8.4x), positioning it well for continued operations and strategic investments.
Stryker shows high-quality fundamental performance with double-digit revenue growth, solid margin structure, and strong free cash flow conversion. Financial health appears sound, supported by good liquidity and manageable leverage, while profitability remains robust for a medical device company. The main watchpoints are debt load, interest coverage, and whether growth can continue without margin compression.
Why Buy Stryker Corp. Stock? SYK Key Strengths
- Strong revenue growth of 11.2% YoY with net income growth of 8.5%, indicating sustained market demand
- Excellent profitability metrics with 64% gross margin and 19.5% operating margin, demonstrating pricing power and operational efficiency
- Robust free cash flow generation of 4.3B with 17.1% FCF margin, providing substantial flexibility for dividends, debt reduction, and acquisitions
- Conservative capital structure with 0.66x debt/equity ratio and 8.4x interest coverage, indicating low financial distress risk
- Strong liquidity position with 1.89x current ratio and 1.21x quick ratio, ensuring operational flexibility
- Double-digit revenue growth with positive EPS and net income expansion indicates durable operating momentum
- Strong gross margin and healthy operating margin support resilient profitability
- Free cash flow generation is strong, with a 17.1% FCF margin and liquidity metrics that suggest balance sheet flexibility
SYK Stock Risks: Stryker Corp. Investment Risks
- High long-term debt of 14.9B representing 63% of total liabilities, though well-managed with strong interest coverage
- ROE of 14.5% is solid but not exceptional, suggesting moderate efficiency in deploying shareholder capital
- Capital intensity with CapEx of 761M annually may limit flexibility during economic downturns
- Long-term debt remains meaningful and could limit flexibility if acquisition activity or rates pressure financing costs
- Interest coverage is adequate but not exceptionally high, leaving less cushion if earnings weaken
- Net margin growth trails revenue growth slightly, which may indicate some cost pressure or mix-related margin dilution
Key Metrics to Watch
- Revenue growth trajectory and organic growth vs. acquisition-driven growth
- Operating margin sustainability and gross margin trends
- Free cash flow conversion and capital allocation decisions
- Debt reduction progress and leverage ratio trends
- Return on equity improvement and capital efficiency metrics
- Operating margin and interest coverage
- Free cash flow conversion relative to net income
Stryker Corp. (SYK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Stryker Corp. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SYK Profit Margin, ROE & Profitability Analysis
SYK vs Healthcare Sector: How Stryker Corp. Compares
How Stryker Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Stryker Corp. Stock Overvalued? SYK Valuation Analysis 2026
Based on fundamental analysis, Stryker Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Stryker Corp. Balance Sheet: SYK Debt, Cash & Liquidity
SYK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Stryker Corp.'s revenue has grown significantly by 47% over the 5-year period, indicating strong business expansion. The most recent EPS of $8.25 reflects profitable operations.
SYK Revenue Growth, EPS Growth & YoY Performance
SYK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.5B | $834.0M | $2.16 |
| Q2 2025 | $5.4B | $825.0M | $2.14 |
| Q1 2025 | $5.2B | $654.0M | $1.69 |
| Q3 2024 | $4.9B | $692.0M | $1.80 |
| Q2 2024 | $5.0B | $738.0M | $1.93 |
| Q1 2024 | $4.8B | $592.0M | $1.54 |
| Q3 2023 | $4.5B | $692.0M | $1.80 |
| Q2 2023 | $4.5B | $656.0M | $1.72 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Stryker Corp. Dividends, Buybacks & Capital Allocation
SYK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Stryker Corp. (CIK: 0000310764)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774387076.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774386885.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774386697.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774386464.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774386261.xml | View → |
❓ Frequently Asked Questions about SYK
What is the AI rating for SYK?
Stryker Corp. (SYK) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are SYK's key strengths?
Claude: Strong revenue growth of 11.2% YoY with net income growth of 8.5%, indicating sustained market demand. Excellent profitability metrics with 64% gross margin and 19.5% operating margin, demonstrating pricing power and operational efficiency. ChatGPT: Double-digit revenue growth with positive EPS and net income expansion indicates durable operating momentum. Strong gross margin and healthy operating margin support resilient profitability.
What are the risks of investing in SYK?
Claude: High long-term debt of 14.9B representing 63% of total liabilities, though well-managed with strong interest coverage. ROE of 14.5% is solid but not exceptional, suggesting moderate efficiency in deploying shareholder capital. ChatGPT: Long-term debt remains meaningful and could limit flexibility if acquisition activity or rates pressure financing costs. Interest coverage is adequate but not exceptionally high, leaving less cushion if earnings weaken.
What is SYK's revenue and growth?
Stryker Corp. reported revenue of $25.1B.
Does SYK pay dividends?
Stryker Corp. pays dividends, with $1,284.0M distributed to shareholders in the trailing twelve months.
Where can I find SYK SEC filings?
Official SEC filings for Stryker Corp. (CIK: 0000310764) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SYK's EPS?
Stryker Corp. has a diluted EPS of $8.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SYK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Stryker Corp. has a BUY rating with 86% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is SYK stock overvalued or undervalued?
Valuation metrics for SYK: ROE of 14.5% (sector avg: 15%), net margin of 12.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SYK stock in 2026?
Our dual AI analysis gives Stryker Corp. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is SYK's free cash flow?
Stryker Corp.'s operating cash flow is $5.0B, with capital expenditures of $761.0M. FCF margin is 17.1%.
How does SYK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 12.9% (avg: 12%), ROE 14.5% (avg: 15%), current ratio 1.89 (avg: 2).